Author

C. Viant

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 4

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 4 Research Focus:host-pathogen & immune response· 4 Organism:human· 4 Assay:proteomics· 4 Research Focus:cell type annotation· 1 Research Focus:clustering· 1 Assay:flow cytometry· 1 Assay:metagenomics· 1

Frequent Co-Authors

A. Gazumyan· 4 shared C. Gaebler· 4 shared F. Muecksch· 4 shared M. Caskey· 4 shared M. Cipolla· 4 shared S. Finkin· 4 shared T. Hatziioannou· 4 shared V. Ramos· 4 shared

Activity by Year

2020-2021 · peak 3/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

4 shared papersImmunology

A. Gazumyan

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

Naturally enhanced neutralizing breadth to SARS-CoV-2 after one year

Z. Wang, F. Muecksch, D. Schaefer-Babajew, S. Finkin, C. Viant, C. Gaebler, H.- H. Hoffmann, C. O. Barnes, M. Cipolla, V. Ramos, T. Y. Oliveira, A. Cho, F. Schmidt, J. D. Silva, E. Bednarski, , M. C. Nussenzweig

This study shows that convalescent individuals with or without vaccination maintain neutralizing activity and memory B cells against SARS-CoV-2 for up to one year, with vaccination enhancing breadth and potency against variants.

Nature · Jun 14, 2021Peer-reviewedImmunology

Evolution of Antibody Immunity to SARS-CoV-2

C. Gaebler, Z. Wang, J. C. C. Lorenzi, F. Muecksch, S. Finkin, M. Tokuyama, A. Cho, M. Jankovic, D. Schaefer-Babajew, T. Y. Oliveira, M. Cipolla, C. Viant, C. O. Barnes, A. Hurley, M. Turroja, , R. Patel

This study examines the evolution of antibody immunity to SARS-CoV-2 over time, finding that memory B cells evolve with increased potency and resistance to mutations.

bioRxiv · Nov 3, 2020Immunology

Enhanced SARS-CoV-2 Neutralization by Secretory IgA in vitro

Z. Wang, J. C. C. Lorenzi, F. Muecksch, S. Finkin, C. Viant, C. Gaebler, M. Cipolla, H.-H. Hoffman, T. Y. Oliveira, D. A. Oren, V. Ramos, L. Nogueira, E. Michailidis, D. F. Robbiani, A. Gazumyan, , M. C. Nussenzweig

This study shows that secretory IgA, particularly dimers, are more potent than IgG in neutralizing SARS-CoV-2 in vitro, suggesting their importance for mucosal protection and vaccine design.

bioRxiv · Sep 9, 2020 · PreprintImmunology

Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals

D. F. Robbiani, C. Gaebler, F. Muecksch, J. Cetrulo Lorenzi, Z. Wang, A. Cho, M. Agudelo, C. Barnes, S. Finkin, T. Hagglof, T. Oliveira, C. Viant, A. Hurley, K. Millard, R. Kost, , Nuss

The paper analyzes antibody responses in convalescent individuals, finding low neutralizing titers but rare potent RBD-specific antibodies with broad antiviral potential.

bioRxiv · May 13, 2020Immunology